Compumedics maintains robust sales momentum but faces FY26 revenue timing challenges due to MEG installation delays and a cautious Somfit D rollout. The company expects solid year-on-year growth and positions for improved execution in FY27.
- Strong sales order momentum sustains medium-term revenue visibility
- FY26 revenue impacted by MEG installation delays and Somfit D manufacturing focus
- SaaS and annuity platforms expand, enhancing recurring revenue mix
- Cost discipline and US commercial reset support earnings resilience
- FY26 guidance revised to $62-65 million revenue and $5.5-7 million EBITDA
Timing Delays Temper FY26 Revenue Conversion
Compumedics (ASX:CMP) is navigating a tricky FY26 where strong sales orders clash with slower-than-expected revenue recognition. The company’s advanced magnetoencephalography (MEG) systems face installation scheduling delays exacerbated by helium supply disruptions linked to ongoing Middle East conflicts. This geopolitical factor has pushed revenue that might have been booked this financial year into FY27.
Adding to the timing headwinds is a deliberate slowdown in the US rollout of Somfit® D, Compumedics’ home sleep testing device. Management is prioritising manufacturing readiness and deployment quality over speed, delaying the commercial launch until late June or early July. While this cautious approach may dampen near-term revenue, it aims to position the product for sustainable scale in a competitive market.
Robust Order Book and SaaS Expansion Offer Medium-Term Confidence
Despite these timing issues, Compumedics continues to enjoy strong demand across its sleep diagnostics and neurology platforms, supported by a growing pipeline of MEG opportunities. The order book provides clear visibility into future revenue, particularly for FY27, underpinning management’s confidence in a rebound next year.
Notably, the company’s SaaS and annuity revenue streams, including the Nexus 360 platform, are expanding steadily, improving revenue quality and recurring income. This shift towards connected platforms aligns with broader medical device sector trends favouring subscription models over one-off sales.
This momentum is reflected in recent half-year results, where Compumedics reported a 32% revenue surge and a return to profit, driven by MEG sales and SaaS growth. These results set a foundation for the company’s updated FY26 guidance, which anticipates revenue of $62 million to $65 million and EBITDA between $5.5 million and $7 million, representing 22% to 28% growth on FY25. The revised outlook factors in the deferral of MEG revenue and a later Somfit® D contribution but still signals solid underlying performance.
US Market Reset and Cost Discipline Bolster Earnings
The US business remains a mixed story, with capital equipment sales underperforming expectations. Management has responded with a targeted commercial reset involving leadership changes, cost base realignment, and a sharpened focus on execution and conversion. Early signs suggest Somfit and Nexus 360 continue to demonstrate underlying demand, which the company expects to translate into improved momentum post-launch.
Cost discipline remains a cornerstone of Compumedics’ strategy, partially offsetting revenue timing delays. The US cost base reset implemented in January and ongoing supplier reviews support earnings resilience. Combined with higher revenue scale, these measures have helped sustain EBITDA despite the timing challenges.
Liquidity and Growth Initiatives Position Compumedics for FY27
Compumedics’ liquidity position is solid, bolstered by material cash receipts from MEG sales in Q3 FY26 and expanded working capital facilities providing $10 million to $11 million in available headroom. This financial flexibility supports ongoing operations and key growth initiatives.
Looking ahead, the company is focused on converting its strong order pipeline into installations and revenue, scaling SaaS platforms, and executing the Somfit® D rollout with a quality-first approach. Management’s confidence in FY27 growth is anchored on these factors alongside improving US market execution.
While FY26 is challenged by external supply constraints and deliberate pacing, Compumedics’ underlying demand and technology portfolio remain intact. The company’s approach reflects a balancing act between managing near-term timing impacts and setting the stage for sustainable expansion.
Bottom Line?
Compumedics’ FY26 is marked by timing delays rather than demand weakness, with FY27 execution and MEG installations key to unlocking growth.
Questions in the middle?
- How quickly can Compumedics convert its strong MEG order book into revenue amid ongoing helium supply risks?
- Will the cautious Somfit D rollout translate into durable market penetration or delay revenue recovery?
- Can the US commercial reset reverse underperformance and catalyse growth in key capital equipment segments?